Precision BioSciences Q2 2026: Wider Loss on Non-Cash Warrant Charge, But Cash Runway Through 2028 and Promising HBV/DMD Data

summarizeSummary

A wider Q2 net loss was driven by a non-cash warrant liability charge, but Precision BioSciences ended the quarter with $112.4M in cash, enough to fund operations through 2028. Positive clinical updates for the HBV and DMD gene editing programs were provided, with key data milestones expected by year-end 2026.

check_boxKey Events · Earnings and Guidance · DTIL

• Q2 Net Loss Wider on Non-Cash Charge

  Net loss of $32.7M ($1.26/share) vs $23.5M ($2.13/share) in Q2 2025, driven by a $13.9M non-cash loss from warrant liability fair value adjustment due to stock price appreciation. This does not impact cash or operations.

• Cash Runway Through 2028

  Cash, cash equivalents, and restricted cash totaled $112.4M as of June 30, 2026. Management expects this, along with fiscal discipline and the ATM facility, to fund operations through 2028, covering key data milestones for PBGENE-HBV and PBGENE-DMD.

• PBGENE-HBV Clinical Proof-of-Concept

  First clinical biopsy evidence of direct cccDNA elimination: a 1-log reduction with <1% remaining after two doses. Sustained pgRNA loss in 100% of evaluable patients. No dose-limiting toxicities. Additional updates expected by year-end 2026.

• PBGENE-DMD Trial Advancing

  Phase 1/2 FUNCTION-DMD trial now actively recruiting at two sites (Arkansas Children's, Washington University). Initial safety data expected by year-end 2026. Program eligible for Priority Review Voucher.

auto_awesomeAnalysis · DTIL · Life Sciences

A wider-than-expected Q2 net loss of $32.7 million, or $1.26 per share, stemmed from a $13.9 million non-cash charge tied to the revaluation of warrant liabilities as the stock price rose—an accounting adjustment that leaves cash and operations untouched. More importantly, the company closed the quarter with $112.4 million in cash, a balance management believes will fund operations through 2028 and cover key data milestones for its wholly owned gene editing programs, PBGENE-HBV and PBGENE-DMD. On the clinical front, the first-ever biopsy evidence showed that PBGENE-HBV can directly eliminate cccDNA in chronic hepatitis B patients, with sustained loss of pgRNA in all evaluable patients. Meanwhile, the DMD program is actively recruiting at two sites, and initial safety data are expected by year-end 2026. The filing also notes recent leadership changes and addition to the Russell 2000 Index. The non-cash loss is a mark-to-market adjustment, not a cash outflow or new dilution, and the strong cash position and clinical progress are the key takeaways.